AbCellera Biologics Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · Canada
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-22$4.64 RISE2026-03-27$3.27 PEAK2026-05-29$6.17 127d | -29.5% 64d | Missed | Missed | — | — | +88.7% 63d | Missed |
DROP2025-10-08$6.17 RISE2026-02-05$2.78 PEAK2026-05-04$4.59 208d | -54.9% 120d | Missed | Missed | — | — | +65.1% 88d | Missed |
DROP2025-10-08$6.17 RISE2025-12-17$3.35 PEAK2026-01-22$4.64 106d | -45.7% 70d | Missed | Missed | — | — | +38.5% 36d | Missed |
DROP2025-07-21$5.15 RISE2025-09-03$3.99 PEAK2025-10-08$6.17 79d | -22.5% 44d | Missed | Missed | — | — | +54.6% 35d | Missed |
DROP2025-01-22$3.53 RISE2025-05-23$1.97 PEAK2025-07-21$5.15 180d | -44.2% 121d | Missed | Missed | — | — | +161.4% 59d | Missed |
DROP2025-01-22$3.53 RISE2025-04-08$1.93 PEAK2025-07-07$4.03 166d | -45.3% 76d | Missed | Missed | — | — | +108.8% 90d | Missed |
DROP2024-07-16$3.49 RISE2024-11-18$2.65 PEAK2025-01-22$3.53 190d | -24.1% 125d | Missed | Missed | — | — | +33.2% 65d | Missed |
DROP2024-07-16$3.49 RISE2024-11-15$2.65 PEAK2025-01-22$3.53 190d | -24.1% 122d | Missed | Missed | — | — | +33.2% 68d | Missed |
DROP2024-05-06$4.11 RISE2024-09-06$2.39 PEAK2024-11-11$3.15 189d | -41.8% 123d | Missed | Missed | — | — | +31.8% 66d | Missed |
DROP2024-02-27$5.12 RISE2024-07-05$2.69 PEAK2024-07-16$3.49 140d | -47.5% 129d | Missed | Missed | — | — | +29.7% 11d | Missed |
DROP2023-07-19$7.95 RISE2023-10-27$3.91 PEAK2024-01-08$5.97 173d | -50.8% 100d | Missed | Missed | — | — | +52.7% 73d | Missed |
DROP2023-02-15$9.98 RISE2023-06-27$6.35 PEAK2023-07-19$7.95 154d | -36.4% 132d | Missed | Missed | — | — | +25.2% 22d | Missed |
DROP2023-02-03$11.18 RISE2023-05-09$5.66 PEAK2023-07-19$7.95 166d | -49.4% 95d | Missed | Missed | — | — | +40.5% 71d | Missed |
DROP2022-11-16$14.52 RISE2023-01-04$9.37 PEAK2023-02-03$11.18 79d | -35.5% 49d | Missed | Missed | — | — | +19.3% 30d | Missed |
DROP2022-08-12$13.68 RISE2022-09-23$9.20 PEAK2022-11-16$14.52 96d | -32.7% 42d | Missed | Missed | — | — | +57.8% 54d | Missed |
1–15 / 23 1 / 2 | |||||||
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
AbCellera Biologics Inc. recently reported past first-quarter 2026 results, with revenue rising to US$8.32 million from US$4.24 million a year earlier, while net loss narrowed slightly to US$43.17 million and the company highlighted interim Phase 1 data for its ABCL635 antibody candidate. The combination of higher revenue, a modest improvement in per-share losses, and early ABCL635 safety and pharmacokinetic data moving the program toward Phase 2 has drawn fresh attention to how AbCellera’s...
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, Stifel raised the firm’s price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $8 from $7 and kept a Buy rating on the shares. The firm said preliminary safety, pharmacokinetic, and pharmacodynamic data from the […]
The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential
2026-05-14. The following slide deck was published by AbCellera Biologics Inc.
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
AbCellera Biologics Inc. ( NASDAQ:ABCL ) defied analyst predictions to release its quarterly results, which were ahead...
AbCellera Biologics Inc. (ABCL) Bank of America Global Healthcare Conference 2026 May 13, 2026 8:01 PM EDTCompany ParticipantsCarl L.
Presentation Operator MessageOperator Bank of America's Annual Healthcare Conference in very toasty Las Vegas. I'm very happy to be joined here on stage with Carl Hansen with AbCellera. Thank you
AbCellera Biologics (NasdaqGS:ABCL) reported positive interim Phase 1 results for its lead asset ABCL635 in treating moderate to severe vasomotor symptoms associated with menopause. The data showed strong target engagement, a favorable safety profile, and support for once monthly dosing. Based on these results, AbCellera is moving ABCL635 into Phase 2 trials, with efficacy data expected in Q3 2026. For investors watching AbCellera Biologics at a share price of $4.95, the move of ABCL635...
AbCellera Biologics Inc (ABCL) progresses its lead program into Phase II, despite reporting a net loss and increased R&D expenses.
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call May 11, 2026 5:00 PM EDTCompany ParticipantsTryn Stimart - Chief Legal Officer, Chief Compliance...
Presentation Operator MessageOperator Good afternoon, and welcome to AbCellera's Q1 2026 Business Update Conference Call. My name is Ben, and I will facilitate the audio portion of today's
AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year. The company reported
ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement.Ended Q1 2026 with total...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ABCL | +39.28% | +61.52% | +80.41% | +205.45% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +36.31% | +67.23% | +83.85% | +192.76% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 10.56M | $36.86M | 0.03% | Added+81.8% | 2026-03-31 |
| RenTech | quant | 1.51M | $5.27M | 0.01% | Trimmed-36.8% | 2026-03-31 |
| Citadel | multi-strat | 1.15M | $4.01M | 0.01% | Added+17.7% | 2026-03-31 |
| StateStreet | passive | 730.2K | $2.55M | 0.00% | Added+5.2% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-18 | Montalbano John S. | Director | P Open-market purchase | 20,000 | $4.77 | +$95.4K |
| 2026-03-02 | Thermopylae Holdings Ltd. | 10% Owner | P Open-market purchase | 38,000 | $3.44 | +$130.7K |
| 2026-02-27 | Booth Andrew | Chief Financial Officer | P Open-market purchase | 42,600 | $3.42 | +$145.7K |
| 2026-02-27 | Thermopylae Holdings Ltd. | 10% Owner | P Open-market purchase | 177,457 | $3.27 | +$580.3K |
| 2026-01-05 | Lecault Veronique | Chief Technology Officer | A Grant / award(deriv) | 539,265 | — | +$0 |
| 2026-01-05 | Stimart Tryn | Chief Legal Officer | A Grant / award(deriv) | 539,265 | — | +$0 |
| 2026-01-05 | Hansen Carl L. G. | Chief Executive Officer | A Grant / award(deriv) | 2,106,505 | — | +$0 |
| 2026-01-05 | Booth Andrew | Chief Financial Officer | A Grant / award(deriv) | 808,898 | — | +$0 |
| 2025-12-19 | Thermopylae Holdings Ltd. | 10% Owner | G Gift | 225,000 | — | +$0 |
| 2025-12-19 | Quake Stephen | Director | A Grant / award(deriv) | 194,932 | — | +$0 |
| 2025-11-26 | Montalbano John S. | Director | P Open-market purchase | 50,000 | $3.57 | +$178.5K |
| 2025-07-01 | Hayden Michael R | Director | A Grant / award(deriv) | 238,864 | — | +$0 |
| 2025-06-16 | Lo Andrew | Director | A Grant / award(deriv) | 238,864 | — | +$0 |
| 2025-06-16 | Montalbano John S. | Director | A Grant / award(deriv) | 238,864 | — | +$0 |
| 2025-03-11 | Thermopylae Holdings Ltd. | 10% Owner | P Open-market purchase | 343,631 | $2.16 | +$742.2K |
| 2025-03-10 | Montalbano John S. | Director | P Open-market purchase | 25,000 | $2.30 | +$57.5K |
| 2025-03-07 | Montalbano John S. | Director | P Open-market purchase | 60,000 | $2.34 | +$140.6K |
| 2025-01-03 | Hansen Carl L. G. | Chief Executive Officer | A Grant / award(deriv) | 2,730,109 | — | +$0 |
| 2025-01-03 | Booth Andrew | Chief Financial Officer | A Grant / award(deriv) | 1,352,054 | — | +$0 |
| 2025-01-03 | Lecault Veronique | Chief Operating Officer | A Grant / award(deriv) | 832,033 | — | +$0 |
| 2025-01-03 | Stimart Tryn | Chief Legal Officer | A Grant / award(deriv) | 832,033 | — | +$0 |
| 2024-12-05 | Thermopylae Holdings Ltd. | 10% Owner | G Gift | 286,000 | — | +$0 |
| 2024-11-26 | Hansen Carl L. G. | Chief Executive Officer | M Option exercise(deriv) | 56,125 | — | +$0 |
| 2024-11-26 | Hansen Carl L. G. | Chief Executive Officer | M Option exercise | 56,125 | $2.70 | +$151.5K |
| 2024-09-24 | Hansen Carl L. G. | Chief Executive Officer | M Option exercise(deriv) | 56,125 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.17 | — | — |
| 2026-05-11 | -0.20 | -0.14 | +29.11% |
| 2026-02-24 | -0.18 | -0.03 | +83.33% |
| 2025-11-06 | -0.16 | -0.19 | -17.28% |
| 2025-08-07 | -0.16 | -0.12 | +26.53% |
| 2025-05-08 | -0.14 | -0.15 | -5.26% |
| 2025-02-27 | -0.15 | -0.12 | +20.76% |
| 2024-11-04 | -0.13 | -0.17 | -30.77% |
| 2024-08-06 | -0.14 | -0.13 | +9.30% |
| 2024-05-07 | -0.16 | -0.14 | +13.28% |
| 2024-02-20 | -0.12 | -0.16 | -33.33% |
| 2023-11-02 | -0.13 | -0.10 | +22.22% |
| 2023-08-03 | -0.12 | -0.11 | +10.81% |
| 2023-05-04 | -0.13 | -0.14 | -6.06% |
| 2023-02-21 | -0.01 | -0.10 | -900.00% |
| 2022-11-08 | 0.05 | 0.08 | +77.78% |